Abstract:Multiple myeloma (MM) is an incurable B-cell malignancy. High-dose chemotherapy with stem cell support has achieved higher response rates than conventional therapy, but few patients remain in long-term remission. Arsenic trioxide (As2O3) is an effective treatment for acute promyelocytic leukemia. Current clinical studies are investigating arsenic as a therapeutic agent for malignancies. The mechanism of cytotoxicity inducted by As2O3 has not been known thoroughly. Constitutively activated NF-κB is a characteristic of different tumor entities including MM clones and malignant plasma cells from MM patients. It plays an important role in maintaining tumor cell proliferation and protecting cell from apoptosis. The study was to explore the possible mechanism of As2O3 effects on MM lines. Materials and methods: The human MM cell lines of KM3 and RPMI8226 were provided by Hematology Institution of Zhejiang University. The concentration of As2O3 in cell culture system was from 0.5μmol/L to 20μmol/L, 24 hours was selected as the termination point of cell culture. Cell culture without As2O3 and first-antibody-dismissed test were enrolled as controls. Both of the MM lines were treated with As2O3 in various concentrations. The restrained proliferation was observed by drawing growth curve. MTT bioassay was used to examine the effect of As2O3 on cell growth and the concentration of 50% growth inhibition( IC50) calculated respectively. Apoptosis and changes of IκB-α protein was observed by flow cytometry(FCM). Changes and subcellular localization of IκB-α protein were observed by fluorescence microscopy. Western blot was also used to analyze the expression of NF-κB in nuclear. Results: As2O3 inhibited the proliferation of both MM lines, and IC50 of KM3 and RPMI8226 was 9.61μmol/L and 8.01μmol/L respectively. After exposure to As2O3, both of the lines were induced to apoptosis. With As2O3 concentration varied from 0.5μmol/L to 20μmol/L the apoptosis rate of KM3 and RPMI8226 was concentration-dependent measured by FCM. After 24 hours treated with 20μmol/L As2O3, the apoptosis rate of KM3 cells was 41.18% while that of RPMI8226 was 65.25%. It seemed that RPMI8226 cell was more sensitive to As2O3. FCM analysis showed a significant increase in the percentage of G2/M phase cells, from 13.74% to 41.72%, and a decrease percentage of S phase cells from 35.11% to 23.96%. The level of IκB-α in cytoplasm was down-regulated after As2O3 stimulation in both cell lines. The down-regulation of IκB-α from 79.68% to 51.57% was confirmed by FCM in KM3 treated with 10μmol/L As2O3 (p<0.01), the effect was concentration-dependent. While the IκB-α in RPMI8226 changed from 79.72% to 34.08% (p<0.01). Immunofluorescence assay showed that IκB-α localized in cytoplasm mostly. The level of IκB-α protein was down-regulated after As2O3 stimulation. The results showed that KM3 and RPMI8226 lines expressed constitutively activity NF-κB and As2O3 down-regulated the constitutive expression of NF-κB in both cell lines but with different kinetics. Conclusions: As2O3 could not only inhibit the proliferation but also induce apoptosis of KM3 and RPMI8226 cells. The mechanisms of its effect on MM cells may include decreasing the constitutive activity of NF-κB, subsequently down-regulating the expression of various gene products controlled by NF-κB, thus inducing apoptosis in MM cells. As2O3 could inhibit the proliferation of MM cells by changing MM cell cycle and inducing G2/M phase arrest.

Clinical Analysis of the Effect of Arsenic Trioxide on Treating Non-Apl Hematologic Malignancy

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

[Inhibition Effect of Arsenic Trioxide on the Growth of Human MDS Cell Line MUTZ-1 Cells].

Mechanism Of Arsenic Trioxide-Induced Apoptosis On Multiple Myeloma Cells.

Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy

Relationship between Changes of Arsenic Levels in Urine and Side Effects among Leukemia Patients Treated with Trioxide Arsenic

Experimental Study on Antitumor Effect and Renal Toxicity of Arsenic Trioxide During Treatment of Hepatocellular Carcinoma

Effects of Arsenic Trioxide on Proliferation, Paracrine and Migration of Cardiac Progenitor Cells

A Summary on Apoptosis of Malignant Tumor Cells Induced by Arsenic Trioxide

An Evidence-based Perspective of Arsenic Trioxide (As<sub>2</sub>O<sub>3</sub>) for Cancer Patients

[Effect of Arsenic Trioxide on Drug Transporting Molecules in Acute Promyelocytic Leukemia Cell Line].

Retrospective analysis of 76 children with acute promyelocytic leukemia

[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].

[The Effect and Mechanism of Arsenic Trioxide on Hepatocellular Carcinoma].

Effect of Arsenic Trioxide on Different Cell Lines Derived from Chronic Myeloid Leukemia.

Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia

[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].

Therapeutic Strategy of Arsenic Trioxide in the Fight Against Cancers and Other Diseases

[Effect of Arsenic Trioxide on the Expression of Apoptosis-Related Genes in NB4 Cells].

Balance Between the Toxicity and Anticancer Activity of Arsenic Trioxide in Treatment of Acute Promyelocytic Leukemia.

When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia